UCL Cancer Institute


Support our work

With your help, we can transform cancer diagnosis, treatment and outcomes.

Advancing cancer research

Philanthropic support enables UCL to train, recruit and support outstanding scientists and clinicians, provide them with cutting-edge equipment and the environment in which to thrive, and enable pilot projects and clinical trials with the potential to revolutionise our approach to cancer.

"The real impact of philanthropy is that it gives the brightest minds the freedom to think – and do – differently; that is where breakthroughs happen.” Professor Tariq Enver, Director of UCL Cancer Institute

Two researchers in lab at UCL Cancer Institute
Developing kinder more effective therapies

Founded through a philanthropic gift from Children with Cancer UK, the UCL Cancer Institute is the hub for cancer research at UCL. The research that takes place here transforms our understanding of the disease in all its forms, facilitating earlier and quicker diagnosis and monitoring of its progression, and contributing to treatments (including in the fields of bio-therapeutics and immunotherapy) that are kinder, better targeted and more effective.  

Philanthropy makes a profound impact on the development of these pioneering treatments such as CAR-T cell therapy, which is revolutionising cancer treatment. Learn more about how patients and their families benefit from and have supported this work.

The Office of the Vice-President (Advancement)  

UCL’s Office of the Vice-President (Advancement) works directly with the 400-strong academic and research community at the UCL Cancer Institute to develop an active worldwide network of friends and supporters. 

We are at a tipping point in the fight against cancer. Every gift, large or small, propels us towards our vision. If you would like to support the work of the UCL Cancer Institute, please donate here

The UCL CAR T programme 

The UCL CAR T-cell programme is the most comprehensive in Europe, encompassing a broad-ranging portfolio of studies actively recruiting patients with B and T-cell malignancies, myeloma, and neuroblastoma.

Vimeo Widget Placeholderhttps://vimeo.com/343606448